Nektar Therapeutics (NKTR) Financials: History & Chart

Nektar Therapeutics(NKTR)

Biotechnology · San Francisco, CA

$40.48-1.74 (-4.13%)

Delayed quote: Oct 6, 2026, 12:50 PM EDT

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

San Francisco, CA

63 employees

www.nektar.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Howard W. Robin

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	54.59M	10.13M	10.86M	21.81M	11.79M	11.18M	10.46M	29.18M	24.12M
Cost of Goods Sold	347K	0.00	151K	0.00	196K	0.00	0.00	7.98M	4.43M
Gross Profit	54.24M	10.13M	10.71M	21.81M	11.59M	11.18M	10.46M	21.20M	19.69M
Gross Profit Margin	99.4%	100.0%	98.6%	100.0%	98.3%	100.0%	100.0%	72.7%	81.6%
Total Operating Expenses	185.46M	52.47M	48.97M	40.90M	43.13M	47.41M	54.99M	6.85M	54.03M
Research & Development	131.77M	39.13M	35.68M	29.71M	27.25M	29.89M	30.48M	28.75M	35.03M
Selling, General & Administrative	53.31M	12.77M	13.29M	11.38M	15.87M	17.07M	24.35M	17.14M	18.96M
Operating Income (EBIT)	-131.22M	-42.34M	-38.26M	-19.09M	-31.53M	-36.23M	-44.53M	14.35M	-34.34M
Operating Margin	-240.4%	-417.9%	-352.3%	-87.5%	-267.4%	-324.2%	-425.8%	49.2%	-142.4%
Income Before Tax (EBT)	-156.74M	-40.30M	-44.84M	-36.05M	-35.55M	-41.78M	-50.83M	7.00M	-37.05M
Interest Income	19.18M	9.35M	4.24M	2.78M	2.82M	1.97M	2.87M	2.94M	3.44M
Interest Expense	30.96M	7.21M	7.94M	9.77M	6.05M	5.39M	4.97M	10.15M	6.02M
Other Income/Expense	-25.52M	2.04M	-6.58M	-16.96M	-4.02M	-5.55M	-6.29M	-7.35M	-2.70M
Net Income	-157.13M	-40.62M	-44.90M	-36.08M	-35.52M	-41.59M	-50.88M	7.26M	-37.06M
Income Tax Expense	64K	2K	64K	31K	-33K	-188K	52K	-259K	9K
Net Profit Margin	-287.8%	-401.0%	-413.4%	-165.4%	-301.3%	-372.2%	-486.4%	24.9%	-153.6%
EBITDA	-130.53M	-42.19M	-38.11M	-18.90M	-31.34M	-36.02M	-44.11M	14.68M	-33.35M
EBITDA Margin	-239.1%	-416.4%	-350.9%	-86.7%	-265.8%	-322.3%	-421.7%	50.3%	-138.3%
Depreciation & Amortization	693K	156K	151K	190K	196K	214K	426K	332K	993K
EPS Basic	N/A	-1.23	-1.82	-1.78	N/A	-2.95	-3.62	0.52	-2.66
EPS Diluted	N/A	-1.23	-1.82	-1.78	N/A	-2.95	-3.62	0.51	-2.66
Weighted Average Basic Shares	33.05M	33.05M	24.74M	20.30M	14.09M	14.09M	14.06M	13.98M	13.95M
Weighted Average Diluted Shares	33.05M	33.05M	24.74M	20.30M	14.09M	14.09M	14.06M	14.24M	13.95M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	55.23M	98.43M	90.12M	92.06M	101.91M	152.91M	114.62M	1.19B
Cost of Goods Sold	0.00	30.69M	36.64M	21.64M	24.90M	19.48M	21.37M	24.41M
Gross Profit	55.23M	67.74M	53.48M	70.42M	77.01M	133.44M	93.24M	1.17B
Gross Profit Margin	100.0%	68.8%	59.3%	76.5%	75.6%	87.3%	81.4%	98.0%
Total Operating Expenses	186.00M	172.94M	190.90M	310.66M	523.11M	513.36M	533.28M	480.98M
Research & Development	117.33M	120.91M	114.16M	218.32M	400.27M	408.68M	434.57M	399.54M
Selling, General & Administrative	68.67M	76.75M	77.42M	92.33M	122.84M	104.68M	98.71M	81.44M
Operating Income (EBIT)	-130.77M	-105.20M	-137.43M	-240.24M	-446.10M	-379.92M	-440.04M	687.93M
Operating Margin	-236.8%	-106.9%	-152.5%	-261.0%	-437.8%	-248.5%	-383.9%	57.6%
Income Before Tax (EBT)	-164.21M	-119.20M	-276.26M	-364.98M	-523.28M	-443.95M	-440.05M	682.73M
Interest Income	10.44M	14.50M	19.01M	6.78M	2.73M	18.28M	46.34M	37.57M
Interest Expense	26.18M	28.11M	25.33M	28.91M	47.31M	37.12M	46.35M	42.78M
Other Income/Expense	-33.44M	-14.00M	-138.83M	-124.75M	-77.18M	-64.03M	-19K	-5.21M
Net Income	-164.08M	-118.96M	-276.06M	-368.20M	-523.84M	-444.44M	-440.67M	681.31M
Income Tax Expense	-138K	-239K	-200K	3.21M	557K	493K	613K	1.41M
Net Profit Margin	-297.1%	-120.9%	-306.3%	-400.0%	-514.0%	-290.6%	-384.5%	57.1%
EBITDA	-129.74M	-100.81M	-129.61M	-228.04M	-431.96M	-367.42M	-429.04M	696.73M
EBITDA Margin	-234.9%	-102.4%	-143.8%	-247.7%	-423.9%	-240.3%	-374.3%	58.4%
Depreciation & Amortization	1.03M	4.39M	7.82M	12.20M	14.15M	12.50M	11.00M	8.80M
EPS Basic	-9.73	-8.68	-21.79	-29.51	-42.90	-37.33	-37.80	56.70
EPS Diluted	-9.73	-8.68	-21.79	-29.51	-42.90	-37.33	-37.80	56.70
Weighted Average Basic Shares	16.87M	13.71M	12.67M	12.48M	12.22M	11.91M	11.67M	12.01M
Weighted Average Diluted Shares	16.87M	13.71M	12.67M	12.48M	12.22M	11.91M	11.67M	12.01M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.